King Pharmaceuticals: Recalculating an Entire Product Line

The King Pharmaceuticals Medicaid rebate settlement required the company to pay $124 million over allegations of inaccurate average manufacturer price and Best Price reporting across its entire product line. The government alleged that King lacked appropriate internal systems and controls and used improper methodologies to calculate the figures, and King agreed to recalculate its pricing across products and years. For someone who works with customer contracts or government pricing, that is the striking part of this case: the correction had to reach the system producing the numbers.

The Department of Justice announced the settlement on November 1, 2005. The alleged reporting failures ran from January 1, 1994 through December 31, 2002. This pharmaceutical fraud case connected underpaid Medicaid rebates with overcharges involving the Public Health Service and Veterans Affairs. The whistleblower was King’s former Director of Contracts and National Accounts, a role close to the commercial agreements behind the reported prices. The whistleblower also brought claims under the false claims laws of 13 states and the District of Columbia. King itself had revealed its internal problems in a series of disclosures to the federal government and cooperated fully in uncovering their full extent.

How Average Manufacturer Price and Best Price Feed Medicaid Rebates

Manufacturers report average manufacturer price and Best Price to the Centers for Medicare & Medicaid Services, and those figures determine what they owe state Medicaid programs. The Medicaid rebate returns part of the government’s drug spending to the program. Underreporting the rebate leaves the manufacturer with money that should have come back to taxpayers.

Best Price looks for the lowest qualifying price available from the manufacturer. Cash discounts, volume discounts, rebates and purchase-contingent free goods can affect it. Certain government prices, including Federal Supply Schedule prices, are excluded. A concession can therefore matter to one calculation and receive different treatment in another. The contract and the customer category are part of the number.

Overcharges Under Public Health Service and Veterans Affairs Pricing

King’s settlement also resolved Public Health Service and Federal Supply Schedule claims. The government alleged that Medicaid received too little in rebates while federal purchasers and subsidized entities paid too much for drugs. Those are different ways for a price-reporting failure to cost the public money.

The 340B ceiling price uses average manufacturer price minus the Medicaid unit rebate amount. That connection can carry a Medicaid price-reporting problem into the prices charged to safety-net providers. A manufacturer can underpay a rebate and overcharge a provider through linked calculations.

The VA Federal Ceiling Price uses non-Federal Average Manufacturer Price, often called non-FAMP. That is a separate measure from Medicaid average manufacturer price. The federal purchasing framework also requires manufacturers of covered drugs to make them available through the Federal Supply Schedule.

What the Contracts Show About the Reported Price

A contract can show the discount promised to the customer, the conditions attached to it and additional value flowing back to the manufacturer. Those terms explain what the reported price is supposed to reflect.

We examine how those terms reached the pricing calculation. A government-pricing employee may know which transactions entered the reported average. Someone in contracting may know why the customer received a concession. Connecting the agreement with its treatment in the calculation can explain a discrepancy neither document explains alone.

The gap between a drug’s stated price and its price after concessions is also an industry issue. The USC Schaeffer Center’s 2020 paper The Association Between Drug Rebates and List Prices examined U.S. brand-drug prices from 2015 through 2018 and found that increases in estimated rebates were associated with increases in list prices. The relationship persisted when the study excluded drugs with high Medicaid share.

That later market study used the difference between list prices and estimated net prices as its rebate measure, including concessions to several kinds of intermediaries. The list price alone cannot explain the commercial bargain. The contract terms and actual concessions supply the detail a pricing insider recognizes.

Recalculating the Entire Product Line

King agreed to recalculate pricing for its entire product line, the remedy that sets this case apart. The government described a company agreeing to redo pricing over several years after alleged failures in the systems and controls behind both reported measures. The agreement called for both a payment and a return to the historical calculations. King also entered a corporate integrity agreement with the HHS Office of Inspector General to ensure that it accurately reports its average manufacturer price and Best Price figures in the future.

For a pricing team, that scope puts the shared methodology at the center of the review: how transactions were selected, how concessions were treated and how the resulting numbers were checked.

The HHS Office of Inspector General reported in September 2019 that CMS had instructed manufacturers not to submit their pricing assumptions routinely. Those records remained inside the company unless CMS sought them for a specific inquiry.

That is why pricing assumptions and restatements belong beside the underlying contracts. For us, the useful question is what changed between the original calculation and the corrected one, and who understood the difference.

What Other Rebate Cases Reveal

Other pricing cases make particular contract terms visible. Bristol-Myers Squibb’s 2021 settlement announcement described allegations that the company improperly deducted wholesaler service fees from average manufacturer price and excluded value received under price-appreciation provisions.

A payment classified as a price concession reduces reported average manufacturer price. A payment for a qualifying service receives different treatment. The alleged improper deductions mattered because lowering the reported average generally reduced the rebate the manufacturer owed Medicaid.

Price-appreciation provisions concern inventory already held by a wholesaler when the manufacturer raises the price. A contract can return part of the wholesaler’s resulting gain to the manufacturer. The government’s allegation was that this additional value belonged in the reported average. A pricing review that stops at the original invoice can miss a later payment that changes what the manufacturer received.

Wyeth’s Protonix rebate case, settled with Pfizer in 2016, concerned bundled hospital discounts. The government alleged that Wyeth tied discounts on oral and intravenous Protonix together and concealed those discounts from Medicaid. It also explained the commercial purpose: patients started on oral Protonix in the hospital were likely to remain on it after discharge, when payers including Medicaid would pay nearly full price. The hospital bargain had consequences beyond the hospital purchase.

Mallinckrodt’s Acthar case shows why the response to a pricing problem matters alongside the calculation. The whistleblower’s amended complaint alleged that the company used an incorrect historical base average manufacturer price to reduce inflation rebates. It also described what happened when an internal calculation put a price on correcting the problem:

The passage connects the calculation with an alleged management decision about who could discuss it. That is evidence of a different kind from the submitted price itself: what people inside the business understood about the money at stake.

Sanofi Pasteur supplies the closest comparison on federal purchasing. In the 2017 VA overcharge settlement, the company had disclosed incorrect Federal Ceiling Price calculations for 2007 through 2011. According to the Justice Department, the VA Inspector General determined that the error caused overcharges going back to 2002. The auditor identified earlier periods affected by the same error.

Each example identifies a different place to look: value returned under a wholesaler contract, a hospital discount, a historical pricing input or earlier quarters affected by the same calculation. King’s case brings the broader question into focus: how far did the reporting problem reach across the business?

What Evidence Is Needed to Prove Fraud?

In a drug-pricing case, the evidence connects the underlying transaction, the reported number, the government payment or rebate, and what the company knew. We work with pricing and contracting insiders to make those connections, reading the contracts, workpapers and certified reports together.

A senior executive or a directly delegated individual certifies each price report. That adds a decision to the evidence trail. The underlying contract explains the commercial terms, the workpaper explains the calculation, and the certified report shows the number the company submitted to the government. We examine the communications around those steps to understand how the people responsible treated the information they had.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

You Know How the Price Was Built

If you worked on customer terms, government-price calculations or a product-line restatement, speak with our whistleblower experts about the numbers you saw. We build your strongest pharmaceutical pricing whistleblower case from what you know, bring in pharmaceutical pricing whistleblower lawyers and stay beside you through the case.